Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 8:52 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1657–1680 of 2,464 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Ovarian Tumors Clear all
Terminated Phase 3 Interventional Results available

Efficacy and Safety of Farletuzumab (MORAb-003) in Combination With Carboplatin and Taxane in Participants With Platinum-sensitive Ovarian Cancer in First Relapse

NCT00849667
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Farletuzumab, Carboplatin, Taxane, Farletuzumab-matched placebo
Drug
Lead sponsor
Morphotek
Industry
Eligibility
18 Years and older · Female only
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
110
States / cities
Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 91 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2022 · Synced Oct 25, 2026, 8:52 AM EDT
Completed Phase 2 Interventional

ISIS 5132 in Treating Patients With Metastatic or Recurrent Ovarian Cancer

NCT00003892
View directory record Official record
Conditions
Ovarian Cancer
Interventions
ISIS 5132
Drug
Lead sponsor
NCIC Clinical Trials Group
Network
Eligibility
18 Years to 120 Years · Female only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2008
U.S. locations
2
States / cities
Duluth, Minnesota • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 6, 2020 · Synced Oct 25, 2026, 8:52 AM EDT
Completed Phase 2 Interventional

Aminocamptothecin in Treating Patients With Recurrent or Unresectable Epithelial Ovarian Cancer

NCT00002671
View directory record Official record
Conditions
Ovarian Cancer
Interventions
aminocamptothecin
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1995
U.S. locations
6
States / cities
Red Bank, New Jersey • Summit, New Jersey • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2012 · Synced Oct 25, 2026, 8:52 AM EDT
Completed Phase 2 Interventional Results available

Paclitaxel and Carboplatin With Or Without Sorafenib In The First-Line Treatment Of Patients With Ovarian Cancer

NCT00390611
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Sorafenib, Paclitaxel, Carboplatin
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older · Female only
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
17
States / cities
Jonesboro, Arkansas • Fort Lauderdale, Florida • Fort Myers, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2014 · Synced Oct 25, 2026, 8:52 AM EDT
Completed Phase 2 Interventional Results available

Sunitinib in Recurrent and Refractory Ovarian, Fallopian Tube and Peritoneal Carcinoma

NCT00768144
View directory record Official record
Conditions
Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
Interventions
Sunitinib
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 24, 2018 · Synced Oct 25, 2026, 8:52 AM EDT
Terminated Early Phase 1 Interventional Results available

Fermented Wheat Germ Extract in Women With Ovarian Cancer

NCT02411565
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Fermented Wheat Germ Extract (FWGE), Placebo, Standard of Care: Planned Surgery, Quality of Life (QoL) Surveys: FACT-O
Drug · Other
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jan 23, 2019 · Synced Oct 25, 2026, 8:52 AM EDT
Completed No phase listed Observational

Ovarian Cancer Patient Questionnaire on Genetic Testing

NCT00486707
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Questionnaire
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
237 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 1, 2012 · Synced Oct 25, 2026, 8:52 AM EDT
Completed Not applicable Interventional

Stress Reduction for Overweight or Obese Women Either With Polycystic Ovary Syndrome (PCOS) or Without PCOS (Non-PCOS)

NCT01464398
View directory record Official record
Conditions
Polycystic Ovary Syndrome, Overweight, Obesity, Stress, Physiological, Stress, Psychological
Interventions
Stress reduction, Stress reduction with Health education
Behavioral
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 14, 2015 · Synced Oct 25, 2026, 8:52 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Comparison of Lifestyle Markers Between Women With and Without Polycystic Ovary Syndrome

NCT01859663
View directory record Official record
Conditions
Polycystic Ovary Syndrome, Dietary Habits, Physical Activity
Interventions
Not listed
Lead sponsor
Cornell University
Other
Eligibility
18 Years to 48 Years · Female only
Enrollment
126 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2022
U.S. locations
3
States / cities
Ithaca, New York • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Feb 9, 2024 · Synced Oct 25, 2026, 8:52 AM EDT
Active, not recruiting Phase 1 Interventional

Depression Treatment and Screening in Ovarian Cancer Patients

NCT00515372
View directory record Official record
Conditions
Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
Interventions
Telephone Counseling, Usual Care
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
409 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 25, 2026, 8:52 AM EDT
Completed Phase 2 Interventional Results available

Evaluation of Metformin, Targeting Cancer Stem Cells for Prevention of Relapse in Gynecologic Patients

NCT01579812
View directory record Official record
Conditions
Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
Interventions
Metformin
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
19 Years to 79 Years · Female only
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated May 25, 2018 · Synced Oct 25, 2026, 8:52 AM EDT
Completed No phase listed Observational

Predictors of Relapse of Ovarian, Peritoneal, and Fallopian Tube Cancers

NCT00086567
View directory record Official record
Conditions
Fallopian Tube Cancer, Peritoneal Neoplasms, Epithelial Ovarian Cancer
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
11
States / cities
Birmingham, Alabama • Los Angeles, California • Evanston, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 25, 2026, 8:52 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Gemcitabine Hydrochloride Alone or With M6620 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

NCT02595892
View directory record Official record
Conditions
Ovarian Serous Tumor, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
Interventions
Berzosertib, Gemcitabine, Gemcitabine Hydrochloride
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
17
States / cities
Phoenix, Arizona • Scottsdale, Arizona • La Jolla, California + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 25, 2026, 8:52 AM EDT
Completed Phase 1 Interventional

AFP464 in Treating Patients With Metastatic or Refractory Solid Tumors That Cannot Be Removed By Surgery

NCT00348699
View directory record Official record
Conditions
Male Breast Cancer, Recurrent Breast Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Primary Peritoneal Cavity Cancer, Recurrent Renal Cell Cancer, Stage IV Breast Cancer, Stage IV Ovarian Epithelial Cancer, Stage IV Primary Peritoneal Cavity Cancer, Stage IV Renal Cell Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
AFP464, pharmacological study, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 24, 2014 · Synced Oct 25, 2026, 8:52 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Enhance the Use of Genetic Counseling and Testing in Latinas

NCT04544501
View directory record Official record
Conditions
Hereditary Breast and Ovarian Cancer Syndrome
Interventions
Culturally-Targeted Video, FORCE Fact Sheet
Behavioral · Other
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
4
States / cities
Washington D.C., District of Columbia • Alexandria, Virginia • Arlington, Virginia + 1 more
Source: ClinicalTrials.gov public record
Updated May 2, 2022 · Synced Oct 25, 2026, 8:52 AM EDT
Withdrawn Phase 1 Interventional

N-acetylcysteine Given IV With Cisplatin and Paclitaxel in Patients With Ovarian Cancer

NCT01138137
View directory record Official record
Conditions
Ovarian Carcinoma, Stage 3 or 4, Epithelial Ovarian Carcinoma, Primary Peritoneal Carcinoma
Interventions
Paclitaxel, N-acetylcysteine, Cisplatin
Drug
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years to 75 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 21, 2017 · Synced Oct 25, 2026, 8:52 AM EDT
Completed Phase 1 Interventional

Rapamycin With Grapefruit Juice for Advanced Malignancies

NCT00375245
View directory record Official record
Conditions
Tumors, Neoplasm Metastasis
Interventions
Rapamycin (sirolimus), Grapefruit Juice
Drug · Other
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 17, 2014 · Synced Oct 25, 2026, 8:52 AM EDT
Completed Not applicable Interventional

Evaluating the Performance of Morphology Index in Surgical Decision-Making for Ovarian Tumors

NCT02227654
View directory record Official record
Conditions
Ovarian Neoplasms
Interventions
Abnormal Ovarian Ultrasound
Procedure
Lead sponsor
Frederick R. Ueland, M.D.
Other
Eligibility
25 Years and older · Female only
Enrollment
179 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Mar 2, 2023 · Synced Oct 25, 2026, 8:52 AM EDT
Completed Phase 1 Interventional

Interleukin-12 in Treating Patients With Refractory Advanced-Stage Ovarian Cancer or Abdominal Cancer

NCT00003439
View directory record Official record
Conditions
Cancer
Interventions
recombinant interleukin-12
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 7, 2013 · Synced Oct 25, 2026, 8:52 AM EDT
Completed Phase 2 Interventional

A Phase II Trial of Cabozantinib With Patients With Refractory GCTs

NCT04876456
View directory record Official record
Conditions
Germ Cell Tumor, Seminoma, Non-seminomatous Germ Cell Tumor, Ovarian Germ Cell Tumor
Interventions
Cabozantinib
Drug
Lead sponsor
Jennifer King
Other
Eligibility
Not listed
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 25, 2026, 8:52 AM EDT
Completed Phase 1 Interventional

Intravenous Palifosfamide-tris in Combination With Etoposide and Carboplatin in Patients With Malignancies

NCT01242072
View directory record Official record
Conditions
Malignancy, Cancer, Non Small Cell Lung Cancer, Small Cell Lung Cancer, Testicular Cancer, Thymoma, Ovarian Cancer, Osteosarcoma
Interventions
palifosfamide-tris
Drug
Lead sponsor
Alaunos Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
4
States / cities
Indianapolis, Indiana • Lafayette, Indiana • Muncie, Indiana + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 25, 2026, 8:52 AM EDT
Not listed Phase 2 Interventional

Study of Paclitaxel, Carboplatin and Oral Metformin in the Treatment of Advanced Stage Ovarian Carcinoma

NCT02437812
View directory record Official record
Conditions
Epithelial Ovarian Carcinoma
Interventions
Metformin, Paclitaxel, Carboplatin
Drug
Lead sponsor
Gynecologic Oncology Associates
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Feb 28, 2017 · Synced Oct 25, 2026, 8:52 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Gyn Onc Prehab Study

NCT04298827
View directory record Official record
Conditions
Gynecologic Cancer, Ovarian Cancer, Endometrial Cancer, Cervical Cancer, Surgery, Treatment Adherence, Quality of Life
Interventions
Unimodal, Trimodal
Other
Lead sponsor
St. Louis University
Other
Eligibility
18 Years to 90 Years · Female only
Enrollment
83 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 8, 2024 · Synced Oct 25, 2026, 8:52 AM EDT
Completed Phase 1 Interventional Results available

FT516 and IL2 With Enoblituzumab for Ovarian Cancer

NCT04630769
View directory record Official record
Conditions
Ovarian Cancer, Fallopian Tube Adenocarcinoma, Primary Peritoneal Cavity Cancer
Interventions
IP FT516, Enoblituzumab, IL-2
Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 3, 2023 · Synced Oct 25, 2026, 8:52 AM EDT